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Abstract.  Thrombospondin (TSP) is a homotrimeric 
extracellular glycoprotein with a  subunit molecular 
mass of 140 kD. The subunits have a modular or 
domain-like structure and are held together by inter- 
chain disulphide bonds.  A  number of domains have 
been identified including those for the binding of col- 
lagen,  fibrinogen, and heparin.  Due to the trimeric 
form of the TSP molecule, the various domains are 
trivalent in nature and this contributes to the ability of 
TSP to mediate cell-substrate interactions.  Indeed, 
TSP has recently been shown not only to promote cell 
adhesion but also to be intimately involved in cell 
growth and migration.  The adhesive function of TSP 
is attributable to the "solid-phase" or matrix-bound 
form of the molecule.  There is some evidence that the 
heparin-binding  domain mediates incorporation of 
soluble TSP into the insoluble matrix  form.  The hepa- 
rin-binding  domain of TSP is a compact globular 
amino-terminal  moiety that contains two clusters of 
basic amino acids and a  single intrachain  disulphide 
bond.  To delineate the role of the heparin-binding  do- 
main in matrix assembly and to define further the pre- 
cise region of interchain disulphide bonding that re- 
suits in trimer formation,  we have expressed deleted 
forms of the cDNA encoding TSP in SV-40-trans- 
formed, African green monkey kidney cells. The pro- 
teins synthesized from the various deleted TSP cDNAs 
were examined for (a)  secretion into the culture 
medium and incorporation into the extracellular ma- 
trix;  (b) binding to heparin-Sepharose;  (c) immu- 
noprecipitability by a conformation-specific monoclo- 
nal antibody; and (d) ability to form trimers.  This 
analysis allowed us to draw the following conclusions. 
(a) A  218 amino acid NH2-terminal protein that pre- 
serves the intrachain  disulphide bridge of the heparin- 
binding domain is capable of binding to heparin- 
Sepharose and incorporating  into the extracellular 
matrix.  (b) A  shorter  164 amino acid NH2-terminal 
peptide that does not contain the intrachain  disulphide 
bridge of the heparin-binding  domain is neither able to 
bind to heparin-Sepharose  nor able to incorporate into 
the extracellular matrix.  (c) The region of interchain 
disulphide bridging necessary for trimer assembly re- 
sides within a cluster of seven cysteine residues im- 
mediately adjacent to the heparin-binding  domain. 
T 
nROMBOSr'ONDIr~ (TSP) ~  was originally  described as 
a component of platelet  alpha  granules  (1), where it 
plays a key role in mediating  the secretion-dependent 
or secondary phase of platelet aggregation  (5, 22). Interest 
in TSP has been stimulated  by the finding that it is synthe- 
sized by a number of normal and transformed cells including 
endothelial  cells, smooth muscle cells; keratinocytes,  fibro- 
blasts, glial cells, macrophages,  squamous carcinoma cells, 
and  type II pneumocytes.  The  newly  synthesized  TSP is 
secreted  and  incorporated  into  the  extracellular  matrix. 
Using immunofluorescence  localization  in tissue sections, 
TSP had been identified in a variety of cellular locations in- 
cluding  muscle,  skin,  kidney,  glandular  epithelium,  and 
blood vessels (see reference 9 for review). 
TSP has been shown to be a potent attachment  factor for 
a variety of cells (33, 35, 36) and has also been found to be 
1. Abbreviations  used in this paper:  HBD, heparin-binding domain; TSE 
thrombospondin. 
an autocrine growth "facilitator"  for aortic smooth muscle 
cells where an increase in TSP gene transcription  occurs as 
an "immediate  early" response to the mitogenic  actions of 
platelet-derived  growth factor (23, 26). Conversely,  agents 
such as heparin  or anti-TSP antibodies which inhibit incor- 
poration of TSP onto the cell surface serve as growth inhibi- 
tors (25).  Heparin has also been shown to inhibit  the TSP- 
induced enhancement  of mitogenic  response to epidermal 
growth factor (24). 
TSP can bind to other constituents  of the extracellular  ma- 
trix, to circulating  polypeptides and to intact  cells.  Bound 
substances  include  fibrinogen,  fibronectin,  plasminogen, 
plasminogen  activator,  type V collagen, and glycosamino- 
glycans (see reference 20 for review). These interactions  are 
mediated by various protease-resistant  regions or domains 
that  compose the TSP molecule.  One such domain is the 
amino-terminal  heparin-binding domain (HBD) that contains 
a high affinity site for heparin.  This domain has been iden- 
tiffed by subjecting  proteolytic fragments  of TSP to hepa- 
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a monomeric peptide whose exact size (Mr 25-30 kD) de- 
pends upon the specific protease used. Since the amino-ter- 
minal amino acid sequence of the HBD is identical to that 
of intact TSP, the HBD occupies the amino terminus of TSP 
(3). The amino acid sequence of the HBD, as predicted from 
the nucleotide sequence ofTSP cDNA, reveals it to be hydro- 
phobic in character and to contain two clusters of basic amino 
acids that probably contribute to the binding of anionic hepa- 
rin (6, 18, 21). There are only two cysteines within the HBD 
that form an intrachain disulphide bond which may help main- 
tain the native conformation of this domain (3, 6). 
A number of findings suggest that the HBD is of major 
physiologic relevance.  Heparin, presumably by binding to 
the HBD, inhibits the incorporation of radioiodinated TSP 
into isolated fibroblast cell matrices and also inhibits the in- 
corporation of newly synthesized TSP into the matrix of aor- 
tic smooth muscle cells (23, 28). This is thought to be an in- 
tegral part of the mechanism by which heparin exerts its 
growth inhibitory effect on aortic smooth muscle cells (23). 
Recent evidence suggests that the cell surface receptor for 
TSP is a heparan sulphate proteoglycan and that heparin, by 
competing for the binding of TSP to its receptor, is capable 
of inhibiting cell surface association (30,  31). Electron mi- 
croscopy of rotary-shadowed, intact TSP demonstrates the 
HBD to be a highly compact globular structure at one end 
of the molecule which is connected to the opposite globular 
end by a thin connecting stalk (10). The three TSP subunits 
appear to be interconnected via the stalks at a point just distal 
to the carboxy terminus of the HBD. The stalk-like connect- 
ing region also contains a binding site for collagen (11, 29) 
and thus may contribute to the binding of secreted TSP to the 
cell layer. To directly ascertain the regions of the TSP mole- 
cule required for matrix incorporation and trimer assembly 
and to further explore structure-function relationships in the 
biologically important HBD,  we undertook the expression 
and analysis of carboxy-terminal deletions of the TSP mol- 
ecule. 
Materials and Methods 
Isolation of TSP cDNA 
To isolate a full length-coding TSP cDNA,  we screened 105 colonies of a 
human fibrohlast eDNA library using a previously characterized 5' 1.8-kb 
TSP eDNA (6).  Details regarding eDNA library construction, screening, 
subcloning, and DNA sequencing were the same as previously described (6). 
Cell Culture and DNA Transfections 
COS-1 cells (SV-40-transformed, African green monkey kidney) (12) were 
grown in DME supplemented with 10% fetal calf serum, 2 mM glutamine, 
100 U/ml of penicillin, and 100/~g/ml of streptomycin. DNA transfections 
were performed by the calcium phosphate coprecipitation method as previ- 
ously described (32). 
Labeling and lmmunoprecipitation 
COS-I  cells were metabolically labeled 48-60 h after transfection. Cells 
were rinsed with DME lacking cysteine and methionine. Labeling was per- 
formed in 2 ml of the above medium supplemented with 0.5% bovine serum 
albumin and  100/zCi/ml each of [35S]methionine and [35S]cysteine  (New 
England Nuclear, Boston, MA). After 4 h, I ml of complete DME with al- 
bumin was added for an additional 4-h incubation, the medium was col- 
lected, centrifuged to remove cell debris, and protease inhibitors were added 
to a  final concentration of 1 mM phenylmethyl sulfonyl fluoride,  1 mM 
leupeptin, and 20 ~g/ml pepstatin A (Sigma Chemical Co., St. Louis, MO). 
The cell layer was solubilized in a detergent solution composed of 0.5% so- 
dium dodecyl sulphate and the above mentioned protease inhibitor cocktail. 
In some cases, isolated extracelhlar matrices were prepared by the method 
of Gospodarowicz and III (13). Briefly, after removal of media, the cell layer 
was washed with phosphate-buffered saline and then treated for 30 min to 
i  h with buffered saline containing 0.5%  Triton X-100.  The cultures were 
washed  repeatedly  with  phosphate-buffered  saline  until  only  a  few 
cytoskeletons and nuclei could be observed associated with the intact ex- 
tracellular matrix. The matrix so prepared was dissolved in 0.5%  sodium 
dodecyl sulphate and protease inhibitor cocktail. 
For immunoprecipitation studies, aliquots of radiolabeled samples (ei- 
ther media, cell layer, or extracellular matrix) were clarified by centrifuga- 
tion and diluted fivefold in a buffer containing 10 mM Tris-HCI (pH 7.4), 
1% Triton X-100,  1% Na-deoxycholate (Sigma Chemical Co.). This dilution 
step reduced the final concentration of sodium dodecyl sulphate to 0.1%. Af- 
ter dilution, the samples were subjected to immunoprecipitation with either 
an  anti-TSP  polyclonal  antiserum  or  an anti-TSP  monoclonal  antibody 
(A2.5).  In  some  instances  the  immunoprecipitated  material  was  resus- 
pended in 100 #l of l0 mM Tris (pH 7.6) with 1% sodium dodecyl sulphate, 
heated to 90°C for l0 min, spun, and the supernatant reimmunoprecipitated. 
The control antibody used in cases of immunoprecipitation with polyclonal 
anti-TSP antibody was preimmune serum while the control antibody used 
in cases of immunoprecipitation with the anti-TSP monoclonal antibody, 
A2.5,  was purified mouse IgG (Cooper Biomedical,  Inc.,  Malvern,  PA). 
The specificity of the anti-TSP antibodies and the procedure for immuno- 
precipitation has been described previously (2, 5, 36). The antifibronectin 
polyclonal antiserum was a kind gift from Dr. J. McDonald (Washington 
University, St. Louis, MO). Immunoprecipitated material was resolved by 
SDS-PAGE on 10% acrylamide slab gels or on 4-10% acrylamide gradient 
gels using the buffer system of Laemmli as described previously (3). After 
electrophoresis, gels were fixed, treated with EnHance (New England Nu- 
clear), dried, and exposed to XAR film (Eastman Kodak Co.,  Rochester, 
NY) at  -70°C. 
Heparin-Sepharose Affinity Chromatography 
Media from metabolically labeled, transfected COS-1 cells was clarified by 
centrifugation,  adjusted  to a  salt strength of 0.18  M  NaCl,  and applied 
to a  500-/~1 heparin-Sepharose  column that had been preequilibrated in 
0.02 M Tris, pH 7.6, 0.18 M NaCI. The column was step eluted with 0.35 
and 0.5 M NaC1 and 500-t~l fractions collected. Each fraction was subjected 
to immunoprecipitation with an anti-TSP polyclonal antibody as described 
above. The immunoprecipitates were resolved by SDS-PAGE on a 5-15% 
gradient gel and visualized by subsequent autoradiography. 
Construction of TSP Expression Vectors 
The eDNA, cloned in pUC18, was linearized at the unique Bgl II site located 
at position 1,693.  l0/~g of linearized DNA was subjected to digestion with 
nuclease Ba131 according to conditions recommended by the supplier (New 
England Biolabs, Beverley, MA). Aliquots were removed at various inter- 
vals and the reactions terminated by dilution in 10 mM EDTA. After blunt- 
ended repair with the Klenow fragment of Escherichia coli DNA polymer- 
asc, 300 ng of a palindromic synthetic DNA linker was ligated to the free 
ends. The linker sequence was 5"pTAATAGATCTATTA-3' and contained a 
translation termination codon and a Bgl II site. After digestion with excess 
Bgl II, plasmid DNAs were self-ligated and transformed into E. coil strain 
B  p(A) 
I  I 
B  (rerlBg 
Figure  1.  TSP  expression  vector. 
The expression vector pSVL (Phar- 
macia Fine Chemicals) contains an 
SV-40  viral  late  promoter  (dark 
box)  and  VP-I  splice  site (-v-) up- 
stream  of  a  polylinker  sequence. 
The SV-40 late polyadenylation site 
[p(A)] is also noted. Appropriately deleted TSP mutants containing 
a synthetic ochre termination codon and Bgl II site [(Ter)Bg] were 
digested  with Bam HI and Bgl  II.  The Bam  HI  site is within the 
TSP 5' untranslated region. The coding region is represented by the 
cross-hatched area.  The Barn HI-Bgl  II fragment was cloned into 
the Bam  HI site (B) of the pSVL  vector. 
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gel electrophoresis of Sst I-Bgl II-digested bacterial miniprep samples. To 
verify that the termination codon  was  in frame  with the TSP-coding se- 
quence, individual Sst l-Bgl II fragments from relevant plasmids were sub- 
cloned into ml3mpl8 and subjected to dideoxy sequencing. We identified 
four clones terminating at amino acids 449, 333, 218, and 164, respectively. 
Each of the four deletion mutants as well as the full-length TSP eDNA was 
then cloned into the eukaryotic expression vector pSVL (Pbarmacia Fine 
Chemicals, Piscataway,  NJ). This vector contains a SV-40 viral late promoter 
and VP-I splice site located upstream ofa polylinker (Fig.  1). TSP deletions 
were digested with Bam HI and Bgl II and ligated into the Bam HI site of 
the polylinker. Correct orientations were checked by appropriate restriction 
digests. 
Results and Discussion 
Cloning of TSP eDNA and Construction of 
Expression Vectors 
To study the structure-function relationships in the TSP mol- 
ecule we cloned a eDNA for TSP that contained the entire 
coding  sequence.  This  was  accomplished  by  screening  a 
fibroblast eDNA library with a previously characterized 1.8- 
kb partial eDNA for TSP that encoded the amino-terminal 
HBD (6). 
Several  clones  containing  various  size  cDNAs  for TSP 
were isolated. The largest eDNA (designated F2) was 4.6 kb 
in  size.  To confirm the authenticity of this eDNA,  we se- 
quenced it on both strands by the method of Maxam and Gil- 
bert (27). 
The DNA sequence for F2 was essentially identical to the 
sequence  for endothelial  cell  TSP  previously  reported  by 
Lawler and Hynes (21), except for nucleotide position 1,805 
(T instead of C). This results in the alteration of amino acid 
559 (leucine instead of proline). Due to the conservative na- 
ture of this change, it probably represents a polymorphism, 
although a DNA sequencing error cannot be ruled out. The 
fibroblast-derived eDNA sequenced by us is slightly larger 
than the endothelial cell eDNA characterized previously, be- 
ing 45 bp more extended in the 5' direction and 99 bp longer 
in the 3' direction.  Though both the fibroblast TSP eDNA 
(4.6 kb in  size) and the endothelial  TSP eDNA (4.5  kb in 
size) contain the entire coding sequence,  they are not "full 
length", as the size of the mRNA for TSP is "°6.0 kb (18, 26). 
Since neither eDNA contains the canonical polyadenylation 
signal AATAAA, it is probable that they lack 3' untranslated 
sequences. 
All TSP mutations were constructed  by nuclease Bal 31 
digestion  as  described  in  Materials  and  Methods  and 
confirmed by sequence analysis (Fig. 2) before transfection 
and expression in COS-I cells. The positions of insertion of 
the ochre termination codons, which should result in the bio- 
synthesis of truncated molecules, are shown in Fig. 3. All the 
mutations are referred to by the identity of the amino acid 
preceding  the  termination  codon.  The  shortest  deletion, 
Prot64 is thus  composed of 164 amino acids starting  from 
the amino terminus of the mature protein whereas the largest 
deletion,  Pro449, is composed of 449 amino acids from the 
amino terminus.  Also shown in Fig.  3 are the positions of 
the  various cysteine  residues  and  the  single  intrachain  di- 
sulphide  bond  present  in  the  HBD.  It  is  evident  that  the 
amino acid sequence at the carboxy terminus of the HBD is 
extremely cysteine rich. It is in this region that the residues 
involved in interchain disulphide linkage are thought to re- 
side (10, 21). 
Figure 2. Nucleotide sequences of truncated TSP cDNAs. Selected 
Ba131 deletion mutagenesis of a full length-coding  TSP eDNA was 
carried out as described in Materials and Methods. Appropriate re- 
striction  fragments  containing  the  mutagenized  sequences  were 
cloned into M13 phage vectors, single-stranded DNA was isolated, 
and dideoxynucleotide  sequencing was performed. Shown are the 
actual nucleotide sequences at and across the site of insertion of  the 
stop codon. The various mutations are identified by the identity of 
the amino  acid  residue  preceding  the ochre-inserted  termination 
codon.  For instance, the deletion  mutation Pro,49 encodes a pro- 
tein composed of  449 amino acids where the carboxy-terminal resi- 
due is a proline. The amino acids are shown adjacent to the nucleo- 
tide sequence using the single letter code. 
Expression of  Deleted TSP cDNAs in COS-1 Cells 
Each of the pSVL-TSP expression vectors was transfected 
into  COS-1  cells  by  the  calcium  phosphate  method  (32). 
50-64 h after transfection, the cells were metabolically la- 
beled  with  psS]cysteine  and  [35S]methionine  for  4  h  fol- 
lowed by a  4-h chase.  Media and cell layer (cells plus ex- 
tracellular matrix) were harvested separately and immuno- 
precipitated with either a control or anti-TSP polyclonal an- 
tiserum. The results of such an analysis are shown in Figs. 
4 and 5. In all instances we detected a truncated TSP protein 
of the predicted size both in the medium and cell layer of the 
transfected cells. In untransfected control cells, we detected 
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Figure 3. Diagrammatic repre- 
sentation of the TSP molecule 
and the sites of insertion of the 
ochre termination codon.  (A) 
Schematic diagram of the tri- 
meric TSP molecule based on 
rotary-shadowed electron mi- 
crographic  images,  epitope 
mapping, and domain structure 
studies (9, 20). The amino-ter- 
minal  HBD  is  shaded.  (B) 
Single  TSP  subunit  showing 
the  amino-terminal  HBD 
(shaded) connected via a thin 
stalk to the carboxy-terminal 
domain  (not  shaded).  (C) 
Line  representation  of  the 
amino-terminal  half  of  the 
TSP molecule. The position of 
the various cysteine residues 
is indicated by their numbered 
location in the amino acid se- 
quence. Also shown is the sin- 
gle intrachain disulphide bond 
present in the HBD  between 
cysteine residues 150 and 214. 
The cluster of cysteine residues 
that has marked homology to 
a cysteine-rich domain in von 
Willebrand factor and the al- 
pha I chain of type I procolla- 
gen is indicated  by an asterisk. 
Clusters of positively charged 
basic amino acid residues in 
the HBD are indicated (+). 
Figure  4.  Synthesis of trun- 
cated  TSP  proteins  (Pro449 
and  Va1333)  by  transfected 
COS-I cells. COS-1 cells were 
transfected  with  expression 
vectors  encoding  the  Pro449 
and  Va1333 deletion  mutants. 
Untransfected  controls  and 
transfected  cells  were  meta- 
bolically labeled with [35Slme- 
thionine and [3SS]cysteine,  me- 
dia  was  separated  from  cell 
layers, and each was subjected 
to  immunoprecipitation with 
anti-TSP antibody (T; lanes 2, 
4, 6, 8, 10, and 12) or control 
antibody (C; lanes 1, 3, 5, 7, 9, 
and  //).  The  Val333 band  in 
lane 6 is interrupted by a crack 
in the fluorograph. To the right 
of the gels, arrowheads indi- 
cate the position of migration 
of endogenous TSP and fibro- 
nectin (FN). Open triangles in 
the gels show the presence of 
truncated proteins Pro449 and 
Va1333 both  in  the  cell  layer 
and medium of the transfected 
cells.  Molecular  mass  stan- 
dards in kilodaltons  are shown 
to the left. 
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by transfected  COS-I cells. On immunoprecipitation  with anti-TSP 
antibody (T; lanes 3, 6, 8, and 10) but not control antibody (C; lanes 
2, 5, 7, and 9) the presence of truncated protein was detectable  both 
in the medium and cell layer (open arrowheads). Lane 1 contains 
iodinated platelet TSP as a marker. Samples were subjected to two 
rounds of immunoprecipitation  to reduce background  (see Materials 
and Methods). This resulted in loss of fibronectin from the im- 
munoprecipitates  and is thus not seen on autoradiography.  The posi- 
tion of  migration of  endogenous  TSP is shown  to the left. Molecular 
mass standards in kilodaltons are shown to the right. 
only endogenous TSP (Fig. 4, lanes 1, 2, 7, and 8). Transfec- 
tion of COS-1  cells with the pSVL-TSP-Pro,9 expression 
vector resulted in the synthesis of a 48-kD protein present 
both in the medium and cell layer that was immunoprecipi- 
hated by an anti-TSP antibody but not by a control antibody 
(Fig. 4, lanes 3, 4, 9, and 10). The diffuse nature of this band 
is probably due to glycosylation. Pro449 contains two poten- 
tial NH2-1inked glycosylation  sites (Asn-X-Ser/Thr)  at amino 
acid residues 230 and 342 (21). Also immunoprecipitated by 
the anti-TSP antibody was endogenous COS-1 cell TSP and 
a high molecular mass protein of 220 kD. This protein was 
immunoprecipitated by a monospecific antifibronectin poly- 
clonal antibody (data not shown) and its presence in the im- 
munoprecipitates reflects the ability of the TSP and fibronec- 
tin to bind to each other (18a, 19). Expression of the deletion 
mutant pSVL-TSP-Va1333 resulted in the biosynthesis of a 
35-kD protein present both in the cell layer and media of 
transfected COS-1 cells (Fig. 4, lanes 5, 6,//, and 12). Ex- 
pression of sequences that encode the HBD with the intra- 
chain disulphide bridge intact (Thr2,s) resulted in the biosyn- 
thesis of a 24-kD protein (Fig. 5, lanes 8 and 10). The final 
deletion mutant protein (Pro,64), besides being smaller than 
Thr2~8, possesses a  single cysteine. This precludes normal 
intrachain disulfide bond formation and might be expected 
to grossly alter the HBD conformation. Since there is a con- 
siderable body of work to suggest that the transport of a mal- 
folded protein through the secretory pathway may be inhibited 
(7,  8),  it was rather surprising to detect the synthesis of a 
truncated protein of Mr 19 kD by COS-1 cells after transfec- 
tion (Fig.  5, lanes 3 and 6). 
Conformation and Heparin-binding Properties of the 
Truncated TSP Proteins 
To examine whether the deleted TSP proteins assumed a con- 
formation similar to that in the native TSP molecule, we im- 
munoprecipitated the proteins with a conformation-specific 
monoclonal antibody (A2.5). In previous studies (4), we had 
shown that the monoclonal antibody A2.5 is directed against 
the active site of  the HBD of TSP. This conclusion was drawn 
from the fact that while the monoclonal antibody A2.5 im- 
munoprecipitated the HBD of TSP, heparin successfully in- 
hibited the binding of the antibody, presumably by compet- 
ing for the binding site (4).  Given the ability of heparin to 
compete for this antibody binding site, it was concluded that 
this site is stericaUy very close to or is the actual heparin- 
binding  active  site  (4).  Further,  the  antibody  A2.5  will 
recognize the HBD only in its native conformation and not 
when it has been denatured (4). 
The conformation-specific  monoclonal antibody A2.5 was 
able to recognize and immunoprecipitate three of the trun- 
cated proteins (Pr0449, Va1333, and Thr2,8) but was unable to 
identify the shortest truncated protein (Pro,64) (Fig. 6, lanes 
4,  6,  8,  and  I0).  Since  the  Pro,64 protein  represents  the 
HBD without the intrachain disulphide bond, it is likely that 
disruption of this bond leads to a conformational change that 
it is no longer recognizable by the antibody A2.5. In untrans- 
fected control cells, the monoclonal antibody A2.5 immuno- 
precipitated endogenous TSP only (Fig. 6, lane 2). 
All four truncated proteins retain the two clusters of posi- 
tively charged amino acids between Arg23 and Lys32  and be- 
tween Arg77 and Args3 that are important in the binding of 
anionic heparin (21). We next examined the degree to which 
the truncated proteins bound heparin-Sepharose.  We rea- 
soned that quantitating the strength of binding to anionic 
heparin by the various truncated proteins would allow us to 
determine factors other than charge that may be important 
in maintaining the configuration of the heparin-binding ac- 
tive site. 
Medium containing the various labeled truncated proteins 
was allowed to bind to a heparin-Sepharose column which 
was then sequentially eluted with a step-wise salt gradient. 
Eluted  column  fractions  were  immunoprecipitated  with 
anti-TSP polyclonal antisera, resolved by PAGE, and visual- 
ized by autoradiography. Fig. 7 shows the elution profile with 
increasing salt strength of intact TSP, fibronectin, and trun- 
cated proteins from the affinity column. As seen in Fig. 7 A, 
three of the truncated proteins  (Pro,9,  Va1333, and Thr2,s) 
bound to heparin-Sepharose with affinities resembling that 
of the native protein.  The larger truncated proteins Pro449 
and Va1333 were eluted from the column at the highest salt 
strength (0.5 M NaC1). The next smallest truncated protein 
(Thr2,s) was eluted by the 0.35  M  salt wash but the higher 
0.5  M  salt wash was required for complete elution. There 
was some elution of intact TSP in the 0.35  M NaC1 wash. 
This presumably represents a proteolyzed form of TSP that 
has lost one or more of the three HBDs that are normally 
present in the intact molecule and results in a lowered affinity 
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TSP  proteins  with  a  conformation-specific 
anti-TSP monoclonal antibody (A2.5).  Meta- 
bolically  labeled  media  from  untransfected 
COS-I cells and cells transfected with expres- 
sion vectors encoding the various deletion mu- 
tants were immunoprecipitated with the confor- 
mation-specific rnonoclonal antibody (A2.5). 
The immunoprecipitates  were resolved by SDS- 
PAGE and visualized by autoradiography. Im- 
munoprecipitation with monoclonal antibody 
A2.5 (,42.5; lanes 2, 4, 6, 8, and 10) but not 
control antibody (CONTROL; lanes 1, 3, 5, 7, 
and 9) led to the detection of three truncated 
TSP proteins in the media (open arrowheads; 
Pro449, Thr218, and  Va1333). The position  of 
migration  of endogenously  synthesized TSP 
and fibronectin (FN) is shown to the right of  the 
figure. Molecular mass standards in kilodaltons 
are shown to the left. 
for  heparin-Sepharose.  The  smallest  truncated  protein 
Pro~64 did not bind to the heparin-Sepharose column at all 
and was quantitatively recovered in the flow through (Fig. 7 
B, lane/). There thus seemed to be an affinity gradient for 
the binding of the various truncated proteins to anionic hepa- 
rin.  The two  larger truncated  proteins  (Pro,9  and  Va1333) 
had a binding affinity to heparin that resembled that of native 
TSP.  The  next,  shorter  truncation,  Thr2~s, which  main- 
tained both the cluster of positively charged amino acids and 
the intrachain disulphide bond of the HBD, seemed to have 
a somewhat lower affinity as the 0.35 M salt wash was able 
to displace some of the truncated protein from the column 
(Fig. 7 A, lane 6). The increased affinity of truncated pro- 
teins Pr0449 and  Va1333 relative to Thr2~8 may be related to 
their trivalent structure (see below). The truncated protein 
unable  to  bind  heparin  was  the  shortest  deletion mutant 
(Pro~64) which,  while  retaining  the  cluster  of positively 
charged amino acids, no longer had the single intrachain di- 
sulphide bond normally present in the HBD. It can thus be 
argued that, in this shortest truncated protein, the alteration 
in conformation resulting from loss of the single intrachain 
disulphide bond so alters the active site that the clusters of 
positively charged amino acids that compose it are no longer 
accessible to bind to heparin. Media from untransfected con- 
trol cells was  also subjected to heparin-Sepharose affinity 
chromatography and as expected (6) most of the endogenous 
The Journal  of Cell Biology,  Volume 109, 1989  848 Figure 7. Heparin-Sepharose affinity chromatography of truncated TSP proteins. Metabolically labeled media from untransfected COS-1 
cells  and  cells transfected  with the  various expression  vectors was made up to 0.18  M  with  respect to NaCl  and  applied to a  hepa- 
rin-Sepharose column. The column was eluted step-wise with 0.35 and 0.5 M NaCI. Each fraction was immunoprecipitated with an anti-TSP 
antibody. (A) The elution profile with increasing salt strength of the truncated proteins Thr2ta, Va1333, and Pro449. The truncated TSP pro- 
teins are indicated by arrows. The position of migration of endogenous fibronectin (FN) and TSP is shown on the upper right. There was 
appreciable loss of truncated proteins, especially Val333 and Proa49, during affinity chromatography due to nonspecific binding to column 
and plastic tubing. This necessitated longer exposures of the autoradiogram contributing to increased background. (B) Elution profile with 
increasing salt strength of truncated protein Prot64. The position of migration of the truncated protein Prol64 is shown by an open arrow- 
head.  Also shown are the positions of migration of endogenous TSP (migrates on SDS-PAGE as a  180-kD protein) and its proteolyzed 
form which has lost the HBD and migrates on SDS-PAGE as a  140-kD protein. Molecular mass markers in kilodaltons are shown to the 
right of the gels. 
TSP was eluted in the high 0.5  M  salt wash (Fig.  7 A, lanes 
1,  5,  and  9). 
Studies on Trimer Assembly 
The trivalent nature of the TSP molecule enables it to effec- 
tively participate in cross-linking functions such as cell-cell 
and cell-substrate interactions (14,  15). It is remarkable that 
proteins  like  TSP  which  are  composed  of  two  or  more 
subunits are capable of accurate self assembly. It is necessary 
for such subunits to correctly identify their appropriate part- 
ner subunit in a milieu of other proteins in the endoplasmic 
reticulum,  align  themselves  appropriately,  and  enter  into 
legitimate disulphide linkage via correct cysteine residues. It 
is not unreasonable  to expect that a  process as complex as 
this  may depend  upon  self-recognition  elements  that allow 
for subunit identification, alignment, and oligomer assembly 
via intersubunit  disulphide  bonding.  The trimeric nature of 
TSP, coupled  with the availability of conformation-specific 
antibodies  and  functional  assays makes it a  good system in 
Prochownik  et al.  Expression of Thrombospondin Deletions  849 Figure 8.  Studies  on trimer  assembly  of the  truncated  proteins 
Pr0449,  Va1333, and  Thr2js. Metabolically  labeled  medium  from 
COS-I ceils transfected  with expression  vectors encoding the dele- 
tion  mutants  was  subjected  to  immunoprecipitation  with  the 
anti-TSP monoclonal antibody A2.5. The immunoprecipitates  were 
resolved on SDS-PAGE in the absence of reductant  and visualized 
by autoradiography.  The presence of truncated  TSP proteins  is indi- 
cated by open arrowheads.  Lane I  contains iodinated platelet  TSP 
as a marker.  Metabolically  labeled  media from untransfected  cells 
also subjected to immunoprecipitation  with control monocional an- 
tibody (Control  MAb; lane 2), anti-TSP monoclonal antibody (A2.5; 
lane 3), and antifibronectin  antibody (Anti-FN; lane 8). Molecular 
mass markers in kilodaltons  are shown to the right. 
which to explore the "signals" that dictate oligomer assembly. 
To  see  if the  various  truncated  proteins  could  enter  into 
trimer  assembly,  the  immunoprecipitated  complexes  were 
resolved  by  SDS-PAGE  in  the  absence  of reductant  and 
visualized  by subsequent  autoradiography.  If the truncated 
proteins do indeed form trimers then a tripling in their appar- 
ent molecular mass in the absence of reductant would be ex- 
pected.  Fig. 8 shows such an analysis.  Purified platelet TSP 
was iodinated  and electrophoresed  in unreduced  form as a 
marker and it migrated as a trimer of ~540 kD (Fig. 8, lane 
/). When medium from untransfected cells was immunopre- 
cipitated with an antifibronectin antibody, two high molecu- 
lar mass proteins are visualized whose migratory behavior 
is consistent with their being different forms of fibronectin 
(Fig. 8, lane 8).  More specifically, the larger, slower migrat- 
ing  form  is  probably  the  unreduced  dimeric;  while  the 
smaller, faster migrating form is one in which partial proteol- 
Figure  9.  Incorporation  of truncated  TSP  proteins  into  Triton 
X-100-insoluble  matrix.  COS-I cells were transfected with expres- 
sion vectors  encoding the various TSP truncated  proteins.  After 
transfection  the  cells  were  metabolically  labeled  and  Triton 
X-100-insoluble  matrices prepared as described in Materials  and 
Methods.  The  matrices  were  dissolved  in  SDS,  immunopre- 
cipitated  with an anti-TSP antibody,  the precipitated  material  re- 
solved  by SDS-PAGE,  and  visualized  by autoradiography (lanes 
1-4). The presence of  truncated  TSP proteins  is indicated by means 
of a curved arrow. Also shown is the position of migration  of TSP 
(arrowhead) and fibronectin  (FN). Triton X-100-insoluble  matrix 
from untransfected cells was also subjected to immunoprecipitation 
by anti-TSP antibody (lane 5). A nonspecific  protein of Mr 43 kD 
was found to be present  in immunoprecipitates  of transfected  cells. 
Molecular mass markers in kilodaltons  are indicated at the margins 
of the figure. 
ysis has removed the interchain disulphide bridge present at 
the carboxy-terminal end of fibronectin (17).  When medium 
from  untransfected  cells  was  immunoprecipitated  with  an 
anti-TSP monoclonal antibody (A2.5), we detected a protein 
The Journal of Cell Biology, Volume 109, 1989  850 Figure 10. Tabular summary and diagrammatic representation of 
the trimeric TSP molecule including the sites of ochre codon inser- 
tion resulting in synthesis  of  truncated TSP proteins. The table sum- 
marizes the behavior of intact endogenous TSP and the truncated 
TSP proteins. The diagram below the table shows the trimeric na- 
ture of the TSP molecule including the single intrachain disulphide 
bond in the HBD and the sites of ochre codon insertion resulting 
in the synthesis of the four truncated TSP proteins (Pro164, Thr2t8, 
Val333, and  Pro449). The  carboxy-terminal globular  domain  is 
shaded. 
of higher molecular mass that comigrated with the iodinated 
TSP standard (Fig. 8, lane/) and thus presumably represents 
the endogenous trimeric form of TSP (Fig.  8, lane 3). 
Truncated TSP proteins  Pro449 and  Va1333  migrated with 
approximate molecular masses of 180 and 110 kD, respec- 
tively, which is roughly three times their molecular mass in 
the presence of reductant (Fig. 8, lanes 4 and 5). There are 
several faint bands between homotrimeric intact TSP at 540 
kD and homotrimeric Pro~9 (at 180 kD) and Val~33 (at  110 
kD) in lanes 4 and 5 of Fig. 8. These presumably represent 
heterotrimeric forms between endogenous TSP subunits and 
the expressed truncated TSP proteins. The truncated protein 
Thr~,8 which  contains  only  two  cysteine  residues  in  in- 
trachain disulphide linkage did not appreciably alter its mo- 
lecular mass in the nonreduced form (Fig. 8, lane 6). There- 
fore,  Thr2,8 must  not  be  capable  of trimerizing  as  this 
requires at least two additional cysteines to participate in in- 
terchain disulphide linkage. The cysteine residues responsi- 
ble for trimer assembly must therefore be two of the seven 
that lie between Va1333 and Thr2~8 (see Fig. 3). As discussed 
previously, the truncated protein Pro~ is not recognized by 
the conformation-specific monoclonal antibody A2.5 and is 
thus not immunoprecipitated (Fig. 8,  lane 7). 
What are the signals for TSP self-recognition, alignment, 
and oligomerization? They may be sequences or conforma- 
tions within the HBD that display a high but probably tran- 
sient affinity for one another during the process oftrimer as- 
sembly. Whatever their nature (conformation or sequence) 
they must lie within the amino-terminal 333 amino acids as 
it is possible to delete 2/3 of the TSP molecule from the car- 
boxy terminus and yet still retain the information required 
for subunit identification, alignment, and oligomerization. 
Interestingly, the deletion mutant Va133~ disrupts a oysteine- 
rich domain that is present in two other oligomeric proteins, 
namely the alpha 1 chain of type 1 procollagen and the von 
Willebrand factor (16). In these three proteins, the homolo- 
gous domains are similar in length and have nine invariant 
cysteines, thus implying the existence of a common confor- 
mation. It has been postulated that the presence of this com- 
mon cysteine-rich domain adjacent to the region of inter- 
chain disulphide linkage may in some way facilitate the pro- 
cess of oligomer assembly. Even though the deletion mutant 
Va1333 disrupts  the cysteine-rich domain trimerization still 
occurs, suggesting that this highly conserved motif  mediates 
a function other than trimer assembly. 
Incorporation  of Truncated TSP Peptides Into the 
ExtraceUular Matrix 
Previous studies have shown that matrix-bound TSP is resis- 
tant to extraction with nonionic detergents (28).  Given this, 
we asked whether the secreted truncated proteins were incor- 
porated into a Triton X-100-insoluble matrix. The procedure 
for preparation of extracellular matrix from the transfected 
COS-I  cells was essentially identical to that described by 
previous  workers  (13).  Isolated matrices from transfected 
cells were solubilized in SDS and immunoprecipitated with 
polyclonal anti-TSP antiserum. In untransfected cells both 
TSP and fibronectin were detectable in the matrix (Fig. 9, 
lane 5).  Truncated TSP proteins Pro~9 and Val333 were also 
found in the matrix (Fig. 9, lanes 1 and 2).  The truncated 
protein Thr2~8, which is univalent but capable of binding to 
heparin, is also incorporated into the matrix but to a lesser 
extent (Fig. 9, lane 4).  The smallest truncated TSP protein 
(Pro~) that is univalent but unable to bind heparin was not 
detectable in the matrix even on prolonged exposure of the 
autoradiogram (Fig. 9, lane 3). It can thus be postulated that 
for entry of TSP into the extracellular matrix, a functioning 
HBD is necessary. It is likely that TSP initially binds via its 
HBD to heparan sulphate proteoglycans in the extracellular 
matrix. This is supported by the finding that heparin is able 
to competitively inhibit the binding of iodinated intact TSP 
to isolated extracellular matrices (28). 
In summary (Fig.  10), the above studies allow us to con- 
clude that an intact HBD is required for heparin binding and 
matrix incorporation. Further, the region of interchain disul- 
phide linkage lies adjacent to the HBD. It should now be pos- 
sible to define more accurately by site-directed mutagenesis 
the signals involved in TSP subunit recognition, alignment, 
binding, and oligomerization. 
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